KR102385665B1 - 질환을 치료하기 위한 5ht 작용제 - Google Patents

질환을 치료하기 위한 5ht 작용제 Download PDF

Info

Publication number
KR102385665B1
KR102385665B1 KR1020177026528A KR20177026528A KR102385665B1 KR 102385665 B1 KR102385665 B1 KR 102385665B1 KR 1020177026528 A KR1020177026528 A KR 1020177026528A KR 20177026528 A KR20177026528 A KR 20177026528A KR 102385665 B1 KR102385665 B1 KR 102385665B1
Authority
KR
South Korea
Prior art keywords
receptor agonist
pharmaceutical composition
epilepsy
delete delete
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177026528A
Other languages
English (en)
Korean (ko)
Other versions
KR20170118870A (ko
Inventor
스코트 씨 바라반
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority to KR1020227011498A priority Critical patent/KR20220048045A/ko
Publication of KR20170118870A publication Critical patent/KR20170118870A/ko
Application granted granted Critical
Publication of KR102385665B1 publication Critical patent/KR102385665B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177026528A 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제 Active KR102385665B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227011498A KR20220048045A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25
US62/120,726 2015-02-25
PCT/US2016/019368 WO2016138138A1 (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011498A Division KR20220048045A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Publications (2)

Publication Number Publication Date
KR20170118870A KR20170118870A (ko) 2017-10-25
KR102385665B1 true KR102385665B1 (ko) 2022-04-14

Family

ID=56789223

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177026528A Active KR102385665B1 (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020237037303A Pending KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020227011498A Ceased KR20220048045A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237037303A Pending KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020227011498A Ceased KR20220048045A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Country Status (21)

Country Link
US (5) US10874643B2 (enExample)
EP (4) EP3632434A1 (enExample)
JP (5) JP6884703B2 (enExample)
KR (3) KR102385665B1 (enExample)
CN (2) CN113546174A (enExample)
AU (3) AU2016222804C1 (enExample)
BR (1) BR112017018297B1 (enExample)
CA (2) CA2977135C (enExample)
CY (1) CY1125360T1 (enExample)
DK (1) DK3261640T3 (enExample)
EA (2) EA201992474A3 (enExample)
ES (2) ES3060954T3 (enExample)
HR (1) HRP20220822T1 (enExample)
HU (1) HUE059559T2 (enExample)
LT (1) LT3261640T (enExample)
PL (1) PL3261640T3 (enExample)
PT (1) PT3261640T (enExample)
RS (1) RS63426B1 (enExample)
SI (1) SI3261640T1 (enExample)
SM (1) SMT202200276T1 (enExample)
WO (1) WO2016138138A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020018839A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Compounds and methods for synergistic activation of m channels
BR112021001135A2 (pt) * 2018-07-27 2021-04-20 Xenon Pharmaceuticals Inc. compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
CA3141688A1 (en) * 2019-05-29 2020-12-03 The Regents Of The University Of California Methods and compositions for treating epilepsy
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
AU2020395254B2 (en) * 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
IL307194A (en) * 2021-03-25 2023-11-01 Maplight Therapeutics Inc Pharmaceutical compositions comprising zolmitriptan
CN117750957A (zh) * 2021-03-25 2024-03-22 地图之光治疗股份有限公司 包含佐米曲坦的药物组合物
CA3221934A1 (en) * 2021-06-01 2022-12-08 Arena Pharmaceuticals, Inc. Methods of treatment
CA3221395A1 (en) * 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
US20250120951A1 (en) * 2021-07-30 2025-04-17 Epygenix Therapeutics, Inc. Clemizole formulation
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US20250295611A1 (en) * 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
CA3247344A1 (en) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
WO2024118280A1 (en) * 2022-11-30 2024-06-06 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action
WO2026112377A1 (en) * 2024-11-20 2026-05-28 Intra-Cellular Therapies, Inc. Pharmaceutical compositions and methods
CN119564685B (zh) * 2024-12-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用
CN122124198B (zh) * 2026-04-29 2026-07-31 湖北健肽生物科技有限公司 一种具有改善肠胃功能的小麦低聚肽的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US20110052536A1 (en) 2007-09-18 2011-03-03 Shirit Einav Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
AU2002259130A1 (en) 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8642351B2 (en) 2006-09-20 2014-02-04 Waters Technologies Corporation Apparatus and methods of fluid chromatography
EP2134556B1 (en) 2007-04-06 2012-07-18 Koninklijke Philips Electronics N.V. Air pollution sensor system
US20110009351A1 (en) 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
MX2010009110A (es) * 2008-02-19 2010-11-30 Adolor Corp Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor.
JP2011518154A (ja) 2008-04-16 2011-06-23 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−１−｛２−［４’−（３−メトキシプロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの合成に有用なプロセス
CN102088990A (zh) 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
EP2408448A4 (en) 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
WO2010132691A1 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
CN102666537A (zh) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN104936947B (zh) 2013-12-27 2017-03-08 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US20110052536A1 (en) 2007-09-18 2011-03-03 Shirit Einav Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CNS Neuroscience & Therapeutics, vol.20, no.7, pp.651-661(2014.06.17.) 1부.*
Pharmacologyonline, vol.3, pp.214-221(2011.01.01.) 1부.*

Also Published As

Publication number Publication date
PT3261640T (pt) 2022-07-06
PL3261640T3 (pl) 2022-10-31
EP3261640A1 (en) 2018-01-03
HRP20220822T1 (hr) 2022-10-28
RS63426B1 (sr) 2022-08-31
US12447144B2 (en) 2025-10-21
EP4696377A3 (en) 2026-04-29
JP7846506B2 (ja) 2026-04-15
EP3261640A4 (en) 2018-12-19
ES3060954T3 (en) 2026-03-30
CN107530326A (zh) 2018-01-02
EP4696377A2 (en) 2026-02-18
JP2022116307A (ja) 2022-08-09
ES2920886T3 (es) 2022-08-11
US11648237B2 (en) 2023-05-16
JP6884703B2 (ja) 2021-06-09
US20210154171A1 (en) 2021-05-27
EP4043016B1 (en) 2025-10-29
AU2021204261B2 (en) 2023-08-10
US20180028499A1 (en) 2018-02-01
US20200147048A1 (en) 2020-05-14
HUE059559T2 (hu) 2022-12-28
AU2021204261A1 (en) 2021-07-29
AU2016222804C1 (en) 2021-10-14
CA2977135C (en) 2023-08-22
EA201992474A3 (ru) 2020-05-31
WO2016138138A1 (en) 2016-09-01
SMT202200276T1 (it) 2022-09-14
KR20220048045A (ko) 2022-04-19
AU2022203274B2 (en) 2024-08-15
US20230346750A1 (en) 2023-11-02
US20260083706A1 (en) 2026-03-26
CA2977135A1 (en) 2016-09-01
EP3632434A1 (en) 2020-04-08
SI3261640T1 (sl) 2022-10-28
AU2022203274A1 (en) 2022-06-16
JP2021185148A (ja) 2021-12-09
CA3204599A1 (en) 2016-09-01
BR112017018297A2 (pt) 2018-04-17
EP3261640B1 (en) 2022-04-06
CN113546174A (zh) 2021-10-26
BR112017018297B1 (pt) 2023-12-05
LT3261640T (lt) 2022-07-11
US10874643B2 (en) 2020-12-29
EA201992474A2 (ru) 2020-02-28
AU2016222804A1 (en) 2017-08-31
JP2020143087A (ja) 2020-09-10
DK3261640T3 (da) 2022-07-11
AU2016222804B2 (en) 2021-07-15
CN107530326B (zh) 2021-09-21
KR20170118870A (ko) 2017-10-25
CY1125360T1 (el) 2025-05-09
JP2024009839A (ja) 2024-01-23
JP2018506555A (ja) 2018-03-08
EA201791882A1 (ru) 2018-02-28
KR20230152844A (ko) 2023-11-03
EP4043016A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
US12447144B2 (en) 5HT agonists for treating disorders
US12419866B2 (en) Compounds and methods for treating an epileptic disorder
HK40062533A (zh) 用於治疗病症的5ht激动剂
HK40079848A (en) The 5ht agonist clemizole for use in treating epilepsy disorders
EA046651B1 (ru) Агонисты 5ht для лечения нарушений
EA040818B1 (ru) Способ лечения эпилептического расстройства с помощью агониста рецептора 5ht

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4